The cholesterol medicine simvastatin, which is one of the most commonly used pharmaceuticals in the world, also has a beneficial effect on the immune defense system with regard to diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. Danish researchers have now explored why this is so, and their findings may result in improved treatment.  Read on.

A surge of new MS treatments have been for the relapsing-remitting form of the disease. A new drug that targets CD20-positive B cells may change that.  Read on.

Could simply thinking about exercise – without so much as lifting a finger – really do the trick?
It sounds incredibly unlikely, but ‘motor imagery’ is a technique often used by top athletes, and some studies suggest that you can use it to improve your strength by mental training alone.
Trust Me, I’m a Doctor teamed up with The University of Northampton’s Professor Tony Kay to put this wonderfully weird idea to the test  Read on

Scientists in the US have discovered a new series of lymphatic vessels in the body that link the brain to the immune system – a connection researchers had previously thought didn’t exist.

The discovery could not only prompt a rewrite of the textbooks, it might also lead to a new understanding of how our immune system influences our brain and our behaviour. Read on.

The report slams the current provision of care for people with long-term neurological conditions, describing it as unsatisfactory from all perspectives, including those of patients, carers and commissioners (the people who plan and buy services). It draws a picture of care that is centred around institutions rather than patients, and cautions that this lack of integrated care results in delayed access to expert advice, particularly in times of crisis.  Read on.

Biogen and AbbVie have been granted EU marketing authorization forZinbryta (daclizumab), to treat adult patients with relapsing forms of multiple sclerosis. Relapse frequency per year was shown to be reduced by up to 45% against other treatments, and 54% against placebo.  Read on.

Results from the 24-month extension of the phase 2 BOLD study demonstrated no new safety concerns and low disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) treated with siponimod.  Read on.